 CAMBRIDGE, Mass., July 09, 2021 GLOBE NEWSWIRE -- Sigilon Therapeutics, Inc. NASDAQ:SGTX, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living TherapeuticsTM platform, today reported that the U.S. Food and Drug Administration FDA has notified the Company that its Phase 12 study of SIG-001 in patients with severe or moderately severe hemophilia A, has been placed on clinical hold. The clinical hold was initiated following the Companys submission of a serious adverse event SAE and temporary enrollment halt to the FDA and other regulatory agencies. 